MoonLake Immunotherapeutics (MLTX) stock
MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.79−0.46 (-4.09%)
Close on Nov 18, 2026Market cap $918.30MP/E –Yield –
MoonLake Immunotherapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
MoonLake Immunotherapeutics's shares outstanding was 74M at Jun 30, 2026. For fiscal 2025 it was 64M, up 2.5% from the year before. The highest annual figure on record is 360M in fiscal 2021.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 64M | +2.5% |
| FY2024 | Dec 31, 2024 | 63M | +28.0% |
| FY2023 | Dec 31, 2023 | 49M | +67.3% |
| FY2022 | Dec 31, 2022 | 29M | -91.8% |
| FY2021 | Dec 31, 2021 | 360M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 74M | +16.8% |
| Q1 FY2026 | Mar 31, 2026 | 71M | +12.7% |
| Q4 FY2025 | Dec 31, 2025 | 68M | +7.8% |
| Q3 FY2025 | Sep 30, 2025 | 63M | +0.8% |
| Q2 FY2025 | Jun 30, 2025 | 63M | +0.6% |
| Q1 FY2025 | Mar 31, 2025 | 63M | +1.0% |
| Q4 FY2024 | Dec 31, 2024 | 63M | +5.1% |
| Q3 FY2024 | Sep 30, 2024 | 63M | +17.5% |
| Q2 FY2024 | Jun 30, 2024 | 63M | +43.8% |
| Q1 FY2024 | Mar 31, 2024 | 63M | +60.4% |
| Q4 FY2023 | Dec 31, 2023 | 60M | +50.3% |
| Q3 FY2023 | Sep 30, 2023 | 54M | +44.9% |
| Q2 FY2023 | Jun 30, 2023 | 44M | +24.2% |
| Q1 FY2023 | Mar 31, 2023 | 39M | +679.1% |
| Q4 FY2022 | Dec 31, 2022 | 40M | +114.2% |
| Q3 FY2022 | Sep 30, 2022 | 37M | +1444.6% |
| Q2 FY2022 | Jun 30, 2022 | 35M | +212.1% |
| Q1 FY2022 | Mar 31, 2022 | 5M | – |
| Q4 FY2021 | Dec 31, 2021 | 19M | – |
| Q3 FY2021 | Sep 30, 2021 | 2M | – |
| Q2 FY2021 | Jun 30, 2021 | 11M | – |
See a number that looks wrong?